Safety Study of Autologous Umbilical Cord Blood Cells for Treatment of Hypoplastic Left Heart Syndrome

Hypoplastic Left Heart Syndrome Clinical Trial

Official title:

Phase I Safety Study of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Stage II Palliation of Hypoplastic Left Heart Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01883076
• Other study ID #: 12-008521
• Status: Completed
• Phase: Phase 1
• Start date: May 15, 2013
• Est. completion date: April 28, 2021

Study information

• Verified date: April 2022
• Source: ReGen Theranostics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase I study to determine the safety and feasibility of injections of autologous umbilical cord blood (UCB) cells into the right ventricle of Hypoplastic Left Heart Syndrome (HLHS) children undergoing a scheduled Glenn surgical procedure. The investigators are doing this research study to find out if autologous stem cells from the individual's own umbilical cord blood can be used to strengthen the muscle of the right side of their heart. This will help determine the safety and feasibility of using cell-based regenerative therapy as an additional treatment for the management of HLHS.

Description:

This study is a Phase I trial to determine the safety of autologous mononuclear cells (MNC) derived from umbilical cord blood for intramyocardial delivery into the right ventricle during a planned and non-emergent Stage II surgical palliation in subjects with HLHS. This is the first critical step towards applying autologous MNC therapy as an add-on regenerative intervention for congenital heart disease management. The choice of HLHS as the target disease for regenerative therapies in congenital heart disease management is multi-factorial and includes the following considerations: 1) Severity of of this incurable disease, 2) palliative nature and burden of long-term outcomes with a single right ventricular system, 3) three stages of planned surgical procedures that provide time points to adjunctively intervene, and 4) prenatal diagnosis enabling planned collection of UCB. An emerging goal for cardiac regeneration includes the application of cell-based technology to congenital heart disease, which is a favorable substrate due to the lack of fibrotic scaring, and the presence of a microenvironment that is expected to support ongoing cardiac proliferation and growth for functional remuscularization. This Phase I safety study will determine the feasibility of collection, processing, and delivery of autologous cells as used in adult cardiac regenerative protocols in the setting of HLHS surgical management.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: April 28, 2021
• Est. primary completion date: April 28, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 18 Months

Eligibility

Inclusion Criteria

1. Individuals with autologous cord blood product that met all cell release criteria (listed on the certificate of analysis from Mayo Clinic Human Cell Therapy Lab) as

follows:

1. No aerobic or anaerobic bacterial growth after 14 days

2. Greater than 70% cell viability pre-freeze

3. Total Nucleated Cells (TNC) concentration of 30-42 x 106 cells/mL (pre-freeze)

4. Minimum of one (1) vial of cells

5. Mononuclear cell percentage of greater than 50%

6. Endotoxin result of less than 16 Endotoxin Units (EU)/mL.

2. Mother's serology test results are negative for HIV, Hepatitis B, and Hepatitis C.

3. Individuals with HLHS having undergone Stage I surgical palliation and undergoing planned Stage II palliative Glenn surgery.

4. Ages up to 18 months are eligible if written informed consent can be obtained from both parents (unless one parent is not reasonably available) and/or legal guardians. Exclusion Criteria

1. Child who's UCB does not meet the specified cell release criteria in Inclusion Criterion #1.

2. History of dimethyl sulfoxide (DMSO) reaction for either the child or mother.

3. Parent(s)/child unwilling to participate.

4. Child with severe chronic diseases, extensive extra-cardiac syndromic features, or history of cancer.

5. Child not completing all pre-procedure work-up within 10 days of the Stage II Glenn surgery as listed in section 6 of this protocol AND lack of pre-procedure work-up documented as a safety concern by a site investigator.

6. Child who's cells have been compromised after meeting cell release criteria (as defined in Inclusion Criterion #1).

7. Child with the following complications of their congenital heart disease:

1. Any condition requiring urgent, or unplanned procedure within 15 days prior to Stage II surgical repair

2. Severe pulmonary hypertension (reported in the medical record as >70% systemic pressure)

3. Other clinical concerns as documented by a site investigator that would predict (more likely to happen than not to happen) a risk of severe complications or very poor outcome during or after Stage II surgical repair.

Related Conditions & MeSH terms

• Hypoplastic Left Heart Syndrome
• Syndrome

Intervention

Biological:
• autologous cell-based delivery
autologous cells (derived from "self")

Locations

Country	Name	City	State
United States	Children's Hospital Colorado	Aurora	Colorado
United States	Children's Hospital Los Angeles	Los Angeles	California
United States	Children's Hospital of Minnesota	Minneapolis	Minnesota
United States	Oklahoma University Children's Hospital	Oklahoma City	Oklahoma
United States	Children's Hospital of Philadelphia	Philadelphia	Pennsylvania
United States	Mayo Clinic	Rochester	Minnesota

Sponsors (7)

Lead Sponsor	Collaborator
Timothy J Nelson, MD, PhD	Children's Hospital Colorado, Children's Hospital Los Angeles, Children's Hospital of Philadelphia, Children's Hospitals and Clinics of Minnesota, Mayo Clinic, University of Oklahoma

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of all-cause mortality		Within 2 years following cell therapy treatment
Primary	Incidence of new and worsening adverse cardiac events	The adverse cardiac events would include sustained/symptomatic ventricular arrhythmias, heart failure, myocardial infarction, cardiac infections, and unexpected cardiovascular surgery.	Within 2 years following cell therapy treatment
Primary	Percentage of subjects whose cells meet all cell release criteria		Up to 2 years
Primary	Percentage of subjects enrolled who undergo cell therapy treatment		Up to 2 years
Secondary	Change in right ventricular ejection fraction at one month according to cardiac imaging with echocardiography		baseline, 1 month
Secondary	Change in right ventricular ejection fraction at 3 months according to cardiac imaging with echocardiography		baseline, 3 months
Secondary	Change in right ventricular ejection fraction at 6 months according to cardiac imaging with echocardiography		baseline, 6 months
Secondary	Change in right ventricle tricuspid annular plane systolic excursion (TAPSE) at one month according to cardiac imaging with echocardiography		baseline, 1 month
Secondary	Change in right ventricle TAPSE at 3 months according to cardiac imaging with echocardiography		baseline, 3 months
Secondary	Change in right ventricle TAPSE at 6 months according to cardiac imaging with echocardiography		baseline, 6 months
Secondary	Change in right ventricle fractional area change at one month according to cardiac imaging with echocardiography		baseline, 1 month
Secondary	Change in right ventricle fractional area change at 3 months according to cardiac imaging with echocardiography		baseline, 3 months
Secondary	Change in right ventricle fractional area change at 6 months according to cardiac imaging with echocardiography		baseline, 6 months

External Links

•   Mayo Clinic Clinical Trials